Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

Open access

Abstract

Background and Objectives Recent advances in blood-based biomarkers offer the potential to revolutionize the diagnosis and management of Alzheimer disease (AD), but additional research in diverse populations is critical. We assessed the profiles of blood-based AD biomarkers and their relationships to cognition and common medical comorbidities in a biracial cohort. Methods Participants were evaluated through the Mayo Clinic Jacksonville Alzheimer Disease Research Center and matched on age, sex, and cognitive status. Plasma AD biomarkers (β-amyloid peptide 1–42 [Aβ42/40], plasma tau phosphorylated at position 181 [p-tau181], glial fibrillary acidic protein [GFAP], and neurofilament light) were measured using the Quanterix SiMoA HD-X analyzer. Cognition was assessed with the Mini-Mental State Examination. Wilcoxon rank sum tests were used to assess for differences in plasma biomarker levels by sex. Linear models tested for associations of self-reported race, chronic kidney disease (CKD), and vascular risk factors with plasma AD biomarker levels. Additional models assessed for interactions between race and plasma biomarkers in predicting cognition. Results The sample comprised African American (AA; N = 267) and non-Hispanic White (NHW; N = 268) participants, including 69% female participants and age range 43–100 (median 80.2) years. Education was higher in NHW participants (median 16 vs 12 years, p < 0.001) while APOE ε4 positivity was higher in AA participants (43% vs 34%; p = 0.04). We observed no differences in plasma AD biomarker levels between AA and NHW participants. These results were unchanged after stratifying by cognitive status (unimpaired vs impaired). Although the p-tau181-cognition association seemed stronger in NHW participants while the Aβ42/40-cognition association seemed stronger in AA participants, these findings did not survive after excluding individuals with CKD. Female participants displayed higher GFAP (177.5 pg/mL vs 157.73 pg/mL; p = 0.002) and lower p-tau181 (2.62 pg/mL vs 3.28 pg/mL; p = 0.001) levels than male participants. Diabetes was inversely associated with GFAP levels (β = −0.01; p < 0.001). Discussion In a biracial community-based sample of adults, we observed that sex differences, CKD, and vascular risk factors, but not self-reported race, contributed to variation in plasma AD biomarkers. Although some prior studies have reported primary effects of race/ethnicity, our results reinforce the need to account for broad-based medical and social determinants of health (including sex, systemic comorbidities, and other factors) in effectively and equitably deploying plasma AD biomarkers in the general population.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000207675

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 39 · Cited by 89

Research works printed but not linked: 2

  1. Centers for Disease Control and Prevention. National Diabetes Statistics Report website [online]. Accessed January 25, 2023. cdc.gov/diabetes/data/statistics-report/index.html.
  2. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System website [online]. Accessed January 25, 2023. nccd.cdc.gov/ckd/default.aspx.

Metadata

Authors
Ramanan, V. K., Graff-Radford, J., Syrjanen, J., Shir, D., Algeciras-Schimnich, A., Lucas, J., Martens, Y. A., Carrasquillo, M. M., Day, G. S., Ertekin-Taner, N., Lachner, C., Willis, F. B., Knopman, D. S., Jack, C. R., Petersen, R. C., Vemuri, P., Graff-Radford, N., & Mielke, M. M.
Affiliations
  • Mayo Clinic (US)
  • From the Department of Neurology (V.K.R., J.G.-R., D.S., D.S.K., R.C.P.), Department of Quantitative Health Sciences (J.S., R.C.P.), and Department of Laboratory Medicine and Pathology (A.A.-S.), Mayo Clinic, Rochester, MN; Department of Psychiatry and Psychology (J.L., C.L.), Department of Neuroscience (Y.A.M., M.M.C., G.S.D., N.E.-T.), Department of Neurology (N.E.-T., C.L., N.G.-R.), and Department of Family Medicine (F.B.W.), Mayo Clinic, Jacksonville, FL; Department of Radiology (C.R.J., P.V.),...
Venue
Neurology
Published
2023-10-03
Volume
101
Issue
14
Pages
e1402-e1411
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4385803548
Cited by
89
References
39
Citations by year
2026: 20 · 2025: 39 · 2024: 28 · 2023: 2
FWCI
18.04
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense
  • Mayo Clinic (U01 AG046139, RR018898, P30 AG062677, P50 AG016574, U01 AG006786, R01AG034676)
  • Eli Lilly and Company
  • Biogen
  • University of Southern California
  • Florida Department of Health
  • Mayo Foundation for Medical Education and Research (AG034676, AG016574, R01-AG034676)
  • Horizon Pharmaceuticals
  • GHR Foundation (R01 AG034676)
  • University of Oxford
  • Eisai
  • Siemens Healthineers
  • National Institutes of Health (AG016574, AG046139, AG062677, AG011378)
  • Genentech
  • National Institute on Aging (R01AG034676, RF1AG051504, U01AG057195, RF1AG077386, U01AG006786, RF1AG069052, K23AG064029, U01AG046139, R01AG061796, U19AG032438, R33AG058738, R01AG041851, R37AG011378, R01AG056366, P30AG062677, U19AG074879, P50AG016574)
  • National Institute of Neurological Disorders and Stroke (R01NS097495)
  • National Center for Research Resources (C06RR018898)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, plasma biomarkers, blood-based biomarkers, phosphorylated tau 181, glial fibrillary acidic protein, neurofilament light chain, cognition, chronic kidney disease, vascular risk factors, diabetes mellitus, sex differences, racial differences, African Americans, non-Hispanic whites, APOE ε4
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Female, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. https://app.cochat.ai/papers/10.1212/wnl.0000000000207675
The paper
Ramanan, V. K., Graff-Radford, J., Syrjanen, J., Shir, D., Algeciras-Schimnich, A., Lucas, J., Martens, Y. A., Carrasquillo, M. M., Day, G. S., Ertekin-Taner, N., Lachner, C., Willis, F. B., Knopman, D. S., Jack, C. R., Petersen, R. C., Vemuri, P., Graff-Radford, N., & Mielke, M. M. (2023). Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Neurology. https://doi.org/10.1212/wnl.0000000000207675

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.